Asprosin-neutralizing antibodies as a treatment for metabolic syndrome

BACKGROUND: Recently, we discovered a new glucogenic and centrally acting orexigenic hormone – asprosin. Asprosin is elevated in metabolic syndrome (MS) patients, and its genetic loss results in reduced appetite, leanness, and blood glucose burden, leading to protection from MS. METHODS: We generate...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:eLife
Autores principales: Mishra, Ila, Duerrschmid, Clemens, Ku, Zhiqiang, He, Yang, Xie, Wei, Silva, Elizabeth Sabath, Hoffman, Jennifer, Xin, Wei, Zhang, Ningyan, Xu, Yong, An, Zhiqiang, Chopra, Atul R
Formato: Artigo
Lenguaje:Inglês
Publicado: eLife Sciences Publications, Ltd 2021
Materias:
Medicine
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8102062/
https://ncbi.nlm.nih.gov/pubmed/33904407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.63784
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares